323 related articles for article (PubMed ID: 33850098)
1. A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis.
Cupo L; Plitman E; Guma E; Chakravarty MM
Transl Psychiatry; 2021 Apr; 11(1):217. PubMed ID: 33850098
[TBL] [Abstract][Full Text] [Related]
2. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence.
Chye Y; Kirkham R; Lorenzetti V; McTavish E; Solowij N; Yücel M
Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jun; 6(6):627-635. PubMed ID: 32948510
[TBL] [Abstract][Full Text] [Related]
3. Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders.
Krebs MO; Kebir O; Jay TM
Eur J Pain; 2019 Aug; 23(7):1225-1233. PubMed ID: 30793421
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids, reward processing, and psychosis.
Gunasekera B; Diederen K; Bhattacharyya S
Psychopharmacology (Berl); 2022 May; 239(5):1157-1177. PubMed ID: 33644820
[TBL] [Abstract][Full Text] [Related]
5. Cannabis-associated psychosis: Neural substrate and clinical impact.
Murray RM; Englund A; Abi-Dargham A; Lewis DA; Di Forti M; Davies C; Sherif M; McGuire P; D'Souza DC
Neuropharmacology; 2017 Sep; 124():89-104. PubMed ID: 28634109
[TBL] [Abstract][Full Text] [Related]
6. Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
Schubart CD; Sommer IE; van Gastel WA; Goetgebuer RL; Kahn RS; Boks MP
Schizophr Res; 2011 Aug; 130(1-3):216-21. PubMed ID: 21592732
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Allendorfer JB; Szaflarski JP
Epilepsy Behav; 2017 May; 70(Pt B):349-354. PubMed ID: 28109780
[TBL] [Abstract][Full Text] [Related]
8. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.
Batalla A; Crippa JA; Busatto GF; Guimaraes FS; Zuardi AW; Valverde O; Atakan Z; McGuire PK; Bhattacharyya S; Martín-Santos R
Curr Pharm Des; 2014; 20(13):2168-85. PubMed ID: 23829359
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids and psychotic symptoms: A potential role for a genetic variant in the P2X purinoceptor 7 (P2RX7) gene.
Boks MP; He Y; Schubart CD; Gastel WV; Elkrief L; Huguet G; Eijk KV; Vinkers CH; Kahn RS; Paus T; Conrod P; Hol EM; de Witte LD
Brain Behav Immun; 2020 Aug; 88():573-581. PubMed ID: 32330591
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids and Psychosis.
D'Souza DC; Radhakrishnan R; Sherif M; Cortes-Briones J; Cahill J; Gupta S; Skosnik PD; Ranganathan M
Curr Pharm Des; 2016; 22(42):6380-6391. PubMed ID: 27568729
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of cannabis: Lessons learned from human experimental studies.
Colizzi M; Bhattacharyya S
Prog Brain Res; 2018; 242():179-216. PubMed ID: 30471680
[TBL] [Abstract][Full Text] [Related]
12. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
14. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
Khalid S; Almalki FA; Hadda TB; Bader A; Abu-Izneid T; Berredjem M; Elsharkawy ER; Alqahtani AM
Curr Pharm Des; 2021; 27(13):1564-1578. PubMed ID: 33267756
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the Risks and Consequences of Adolescent Cannabis Exposure.
Levine A; Clemenza K; Rynn M; Lieberman J
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):214-225. PubMed ID: 28219487
[TBL] [Abstract][Full Text] [Related]
16. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.
D'Souza DC; DiForti M; Ganesh S; George TP; Hall W; Hjorthøj C; Howes O; Keshavan M; Murray RM; Nguyen TB; Pearlson GD; Ranganathan M; Selloni A; Solowij N; Spinazzola E
World J Biol Psychiatry; 2022 Dec; 23(10):719-742. PubMed ID: 35315315
[TBL] [Abstract][Full Text] [Related]
17. The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users.
Lorenzetti V; Solowij N; Yücel M
Biol Psychiatry; 2016 Apr; 79(7):e17-31. PubMed ID: 26858212
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.
Manseau MW; Goff DC
Neurotherapeutics; 2015 Oct; 12(4):816-24. PubMed ID: 26311150
[TBL] [Abstract][Full Text] [Related]
19. The neuropsychopharmacology of cannabis: A review of human imaging studies.
Bloomfield MAP; Hindocha C; Green SF; Wall MB; Lees R; Petrilli K; Costello H; Ogunbiyi MO; Bossong MG; Freeman TP
Pharmacol Ther; 2019 Mar; 195():132-161. PubMed ID: 30347211
[TBL] [Abstract][Full Text] [Related]
20. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV
J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
